Unmasking Early Hepatorenal Fibrosis in Polycystic Kidney Disease Using Noninvasive Precision Molecular MRI of Collagen
- 1Division of Hematology Oncology and Department of Medicine, University of Alabama Birmingham; Birmingham, AL, 30322, USA
Abstract
Fibrosis begins early in autosomal dominant polycystic kidney disease (ADPKD) and drives its progression. Collagen deposition has been observed to increase around cysts in human ADPKD kidneys and livers. Currently, no clinical methods are available to detect early fibrosis before irreversible structural and functional decline. Here, we report fibrosis imaging using Gd-hProCA32.Collagen, a collagen-targeting protein MRI contrast agent for precision molecular MRI (pMRI). Gd-hProCA32.Collagen binds collagen type I with micromolar affinity, exhibiting higher relaxivity than clinical agents at 1.4 T, blood clearance within 72 hours, and no evident acute toxicity. To assess the ability of Gd-hProCA32.Collagen to detect ADPKD-related fibrosis, renal collagen deposition was increased by 11 weeks of age in Pkhd1PCK/PCK (PCK) rats. At 26 weeks, Gd-hProCA32.Collagen, given at a 10-fold lower dose than gadobutrol, produced sustained kidney and liver enhancement through 48 hours, whereas enhancement washed out in wild-type organs and with a non-targeted control protein. Gd-hProCA32.Collagen also increased the number of detected renal cysts per animal by 25% compared with 3% for gadobutrol (P < 0.0001), mainly small and medium cysts outlined by pericystic collagen, and revealed striation-like enhancement at microcyst clusters. Regional enhancement correlated with histological collagen (r = 0.72), whereas gadobutrol enhancement did not (r = 0.21). Kidney and liver enhancement was also observed in a Pkd2 mutant mouse model. These findings reveal a previously inaccessible subclinical fibrotic phase of polycystic kidney and liver disease and support collagen-targeted pMRI for noninvasive detection and mapping of fibrosis when conventional biomarkers remain uninformative.
Related
- Breath molecular feature profiling with machine learning for noninvasive diagnosis of gout: a single-center case-control study
- Metal Hypersensitivity in Total Joint Arthroplasty: Molecular Immunopathogenesis, Diagnostic Controversies, and Prospects for Precision Medicine
- Subtype-Specific Aptamer Technologies for Breast Cancer: From Molecular Recognition to Precision Applications.
- Precision oncology in advanced melanoma: molecular landscapes and personalized therapy recommendations from the Molecular Tumor Board Freiburg.
- Engineering aptamer-based therapeutics for precision cancer immunotherapy: from molecular targeting to clinical applications
BibTeX
@misc{bamishaye2026unmasking,
title = {{Unmasking Early Hepatorenal Fibrosis in Polycystic Kidney Disease Using Noninvasive Precision Molecular MRI of Collagen}},
author = {O. S. Bamishaye and F. Akinlotan and P. H. Chumley and J. Qiao and X. Chen and A. Bennett and R. Ronald and F. Dorabadizare and M. J. Croyle and K. Hekmatyar and A. B. Farris and A. G. Sorace and H. Kim and J.-x. Wang and H. E. Grossniklaus and B. K. Yoder and M. Mrug and J. J. Yang},
howpublished = {bioRxiv},
year = {2026},
month = jul,
doi = {10.64898/2026.07.19.739445},
url = {https://www.biorxiv.org/content/10.64898/2026.07.19.739445v2},
note = {CC BY},
}
RIS
TY - UNPB
TI - Unmasking Early Hepatorenal Fibrosis in Polycystic Kidney Disease Using Noninvasive Precision Molecular MRI of Collagen
AU - O. S. Bamishaye
AU - F. Akinlotan
AU - P. H. Chumley
AU - J. Qiao
AU - X. Chen
AU - A. Bennett
AU - R. Ronald
AU - F. Dorabadizare
AU - M. J. Croyle
AU - K. Hekmatyar
AU - A. B. Farris
AU - A. G. Sorace
AU - H. Kim
AU - J.-x. Wang
AU - H. E. Grossniklaus
AU - B. K. Yoder
AU - M. Mrug
AU - J. J. Yang
PY - 2026
DA - 2026/07/19
PB - bioRxiv
DO - 10.64898/2026.07.19.739445
UR - https://www.biorxiv.org/content/10.64898/2026.07.19.739445v2
AB - Fibrosis begins early in autosomal dominant polycystic kidney disease (ADPKD) and drives its progression. Collagen deposition has been observed to increase around cysts in human ADPKD kidneys and livers. Currently, no clinical methods are available to detect early fibrosis before irreversible structural and functional decline. Here, we report fibrosis imaging using Gd-hProCA32.Collagen, a collagen-targeting protein MRI contrast agent for precision molecular MRI (pMRI). Gd-hProCA32.Collagen binds collagen type I with micromolar affinity, exhibiting higher relaxivity than clinical agents at 1.4 T, blood clearance within 72 hours, and no evident acute toxicity. To assess the ability of Gd-hProCA32.Collagen to detect ADPKD-related fibrosis, renal collagen deposition was increased by 11 weeks of age in Pkhd1PCK/PCK (PCK) rats. At 26 weeks, Gd-hProCA32.Collagen, given at a 10-fold lower dose than gadobutrol, produced sustained kidney and liver enhancement through 48 hours, whereas enhancement washed out in wild-type organs and with a non-targeted control protein. Gd-hProCA32.Collagen also increased the number of detected renal cysts per animal by 25% compared with 3% for gadobutrol (P < 0.0001), mainly small and medium cysts outlined by pericystic collagen, and revealed striation-like enhancement at microcyst clusters. Regional enhancement correlated with histological collagen (r = 0.72), whereas gadobutrol enhancement did not (r = 0.21). Kidney and liver enhancement was also observed in a Pkd2 mutant mouse model. These findings reveal a previously inaccessible subclinical fibrotic phase of polycystic kidney and liver disease and support collagen-targeted pMRI for noninvasive detection and mapping of fibrosis when conventional biomarkers remain uninformative.
ER -